Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Indoximod Formulations in Healthy Volunteers
NCT03852446Phase 1Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Mar 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of indoximod in solid tumor (5 arms), sponsored by Lumos Pharma, Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve up to 20 Days and Serum concentrations (Cmax/Steady State) up to 4 Days. Started Mar 2018; status: completed.
02
Drugs
indoximod
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03852446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852446.